Why Strategic Light Therapies Offer New Hope for People with Parkinson’s Disease

May 10, 2017

Gary Sharpe

Parkinson’s Disease was once thought of as “simply” due to a lack of dopamine production in the brain. Dopamine is the chemical responsible, amongst other things, for the transmission of movement signals between brain and body, and for rewarding specific behaviours with feelings of well-being.

In recent years, we have come to understand the profound importance of the highly complex interplays between various hormones and neurotransmitters in the body and brain. We now know that treating medical issues in terms of a shortage or overproduction of any one of these, in isolation, is highly oversimplistic. We must also consider various imbalances and interactions with other biological chemicals too.

Example: histamine and dopamine

As a specific case in point, there is a distinct interaction between histamine, which is produced through allergic reactions (and we’ve found that many people with PD are very sensitive to this kind of inflammation, especially when it comes to food), and dopamine. In fact, histamine production often results in the suppression of dopamine, and this is why exposure to allergens can markedly impact on PD symptoms in a negative way. Applications of infrared light therapy is now being proven to have a role in combatting allergic responses, and this may be why studies of narrowband infrared treatments for Parkinson’s are showing such promise.

The importance of the interplay between melatonin and dopamine

In healthy people with good sleep patterns, dopamine and melatonin (the hormone responsible for sleepiness) work together in rhythm. During hours of sunlight, dopamine increases and melatonin decreases, while at night melatonin is higher and dopamine levels are at their lowest. In people with PD, not only is dopamine production affected, but its linkage with melatonin is completely broken too. These two chemicals no longer work in rhythm. So, while there may be a shortage of dopamine in people PD, just as critically there may be a corresponding severe over-production of melatonin. It is therefore simply not clear which symptoms and problems encountered in people with Parkinson’s are due to dopamine shortage alone and which are due to the broken interaction between dopamine and melatonin (and other chemicals).

The disaster of the dopamine-melatonin imbalance

One of the consequences is major disruption to sleep patterns in people with PD. Insomnia, daytime fatigue, and several periods of wakefulness during the night are all commonly experienced. Broken sleep patterns, or the disruption of the so-called circadian rhythm, has severe consequences for the health of otherwise well people. For people with chronic neurological diseases such as Parkinson’s, it is potentially disastrous. This is because neuroplasticity (brain self-healing through the creation of new neuronal pathways and the removal of redundant or damaged ones), and processes which remove toxins, dead cells and cell excreta from the brain, typically occur under conditions of prolonged sleep.

What’s wrong with current drug based therapies?

The current standard treatments of Parkinson’s are based on the now outmoded ideas that the disease is due to dopamine shortage alone. The available pharmacological solutions are all aimed at replacing dopamine in the brain or stimulating dopamine producing cells to work harder (and, presumably, as a consequence, to burn out more quickly?), without paying attention to nor addressing the imbalances and interactions with the other hormones or neuro-transmitters. I particularly gasp in horror when I hear that healthcare professionals, who clearly lack this understanding, are prescribing melatonin in a very ad hoc way as a solution to insomnia in PD, thus potentially increasing the imbalances and worsening the symptoms over the long term.

Resetting the balance

A number of important studies have now clearly demonstrated that strategic use of light therapy can be highly beneficial for people with Parkinson’s. Recent studies aimed mainly at addressing the poor quality of sleep associated Parkinson’s, as well as those aimed mainly at addressing depression in people PD, are also inadvertently showing improvements in the motor symptoms of the participants too. It is believed this is because strategic light therapies are actually helping to restore the natural balances between dopamine and melatonin and restoring the circadian rhythm. Previous strategic light therapy research aimed directly at the PD symptoms themselves have shown very significant benefit, with participants in these studies reporting up to 50% improvement and, simultaneously, up to 50% reduction in Parkinson’s medication. Moreover, unlike standard drug therapies for PD, these participants show a stable (non-declining) condition for up to ten years. See my previous articles for further background.

This article was first published on the website Out-Thinking Parkinson’s: www.outthinkingparkinsons.com/. Interested in this topic? Here’s a related article on the same website: Report on Wearable Light Therapy Technology Applied to Parkinson’s Disease.

Image courtesy of 9comeback at FreeDigitalPhotos.net.


Dr. Gary Sharpe, PhD, is a scientist, engineer, writer and digital media expert, diagnosed with Early Onset Parkinson’s Disease eight years ago. Out-Thinking Parkinson’s was created with the help of Deb Helfrich, a philosopher, author and wellness mentor who specializes in astute listening and keen observation. Together, they started developing a method for recovering from Parkinson’s Disease. Today, Out-Thinking Parkinson’s has become a major resource, where Gary and colleagues from around the world, who also have an insider’s perspective of PD, share their knowledge, philosophies and experience of living well with PD, and, also, record their stories of recovery through holistic approaches.

 

Related Articles


Changing Scene

  • The DLC’s New Working Group to Collaborate and Advise on Horticultural Lighting Controls

    May 14, 2024 Lighting and controls manufacturers, engineering and design consultants, non-profits, researchers, and indoor cultivators are among stakeholders recently appointed help the DLC accelerate the horticultural lighting industry’s adoption of networked lighting solutions that advance both crop production and energy efficiency. “The controlled environment agriculture industry has grown steadily since the DLC created its… Read More…

  • CDm2 Lightworks Expands Team in BC’s Interior and Vancouver Island

    May 14, 2024 CDm2 is excited to announce the expansion of their team into the vibrant construction markets of British Columbia’s Interior and Vancouver Island. This expansion is designed to align growth with the dynamic changes in these local economies. “As more companies and industries move to smaller communities, it’s vital that our services grow… Read More…


Design


New Products

  • Introducing MaxLite’s LS3 Series: Controls-Ready LED Strip Lighting

    May 10, 2024 The new generation of LS Series Linear Strips (LS3 Series) features field-selectable wattages, CCTs and field-installable controls. Offered in three sizes (2′, 4′ and 8′), with each providing nine combinations of colour temperatures and wattages, as well as optional c-Max controls, one product can replace 27 different SKUs for stocking distributors! With… Read More…

  • Discover the Power of SATCO|NUVO’s Hi-Pro A21 High Lumen Lamps

    May 10, 2024 SATCO|NUVO’s LED Hi-Pro A21 Lamps offer ColorQuick convenience ideal for commercial projects. Choose from 2700K/4000K/5000K colour temperatures at installation to achieve the desired atmosphere for the environment. Designed to work in 120V to 277V fixtures, these lamps are compatible with ballast bypass fixtures and are dimmable when used in 120V applications. With… Read More…